Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Encorafenib”

83 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 83 results

Testing effectiveness (Phase 2)Study completedNCT05510895
What this trial is testing

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

Who this might be right for
Colorectal CancerColon CancerBRAF V600E+2 more
AIO-Studien-gGmbH 2
Not applicableActive Not RecruitingNCT07022457
What this trial is testing

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Pierre Fabre Ltd 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03839342
What this trial is testing

Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

Who this might be right for
Solid Tumor
University Health Network, Toronto 26
Early research (Phase 1)WithdrawnNCT04759846
What this trial is testing

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Who this might be right for
BRAF V600 MutationUnresectable MelanomaMetastatic Melanoma+1 more
Pierre Fabre Medicament
Testing effectiveness (Phase 2)Active Not RecruitingNCT04526782
What this trial is testing

ENCOrafenib With Binimetinib in bRAF NSCLC

Who this might be right for
Non Small Cell Lung CancerBRAF V600E
Intergroupe Francophone de Cancerologie Thoracique 119
Not applicableStudy completedNCT07649252
What this trial is testing

Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan

Who this might be right for
Melanoma
Novartis Pharmaceuticals 82
Testing effectiveness (Phase 2)Study completedNCT02278133
What this trial is testing

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Who this might be right for
Metastatic Colorectal Cancer
Array BioPharma 20
Early research (Phase 1)Looking for participantsNCT04903119
What this trial is testing

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Who this might be right for
Metastatic MelanomaBRAF Gene Mutation
Rina Plattner 30
Large-scale testing (Phase 3)Active Not RecruitingNCT04607421
What this trial is testing

Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Who this might be right for
Neoplasms
Pfizer 841
Testing effectiveness (Phase 2)Ended earlyNCT04390243
What this trial is testing

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Who this might be right for
Locally Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaRecurrent Pancreatic Carcinoma+2 more
Academic and Community Cancer Research United 6
Testing effectiveness (Phase 2)WithdrawnNCT02263898
What this trial is testing

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Who this might be right for
Recurrent MelanomaStage IV Melanoma
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT01894672
What this trial is testing

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 7
Early research (Phase 1)Ended earlyNCT05743036
What this trial is testing

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc 44
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07178717
What this trial is testing

Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

Who this might be right for
Colo-rectal Cancer
Vall d'Hebron Institute of Oncology 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT03235245
What this trial is testing

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Who this might be right for
Unresectable Stage III MelanomaStage IV Melanoma
European Organisation for Research and Treatment of Cancer - EORTC 271
Testing effectiveness (Phase 2)Active Not RecruitingNCT04324112
What this trial is testing

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Who this might be right for
Hairy Cell Leukemia
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Study completedNCT03693170
What this trial is testing

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Who this might be right for
BRAF V600E-mutant Metastatic Colorectal Cancer
Pierre Fabre Medicament 95
Testing effectiveness (Phase 2)Ended earlyNCT05926960
What this trial is testing

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Who this might be right for
Melanoma
Pfizer 38
Testing effectiveness (Phase 2)Looking for participantsNCT06411600
What this trial is testing

Combination Therapy for BRAF-V600E Metastatic CRCm

Who this might be right for
Metastatic Colorectal Cancer
Vall d'Hebron Institute of Oncology 94
Testing effectiveness (Phase 2)Looking for participantsNCT06887088
What this trial is testing

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Who this might be right for
Melanoma BRAF V600E/K MutatedMelanoma and Brain Metastases
Grupo Español Multidisciplinar de Melanoma 33
Next Page